Rep. Mast Urges Wider Federal Drug Schedule Review Than Rescheduling

What Mast said

According to Marijuana Moment, Mast said, "I want to see an across-the-board examination of cannabis, hemp, psilocybin, tranquilizers—of everything." The outlet described him as a Republican who leads marijuana reform efforts on Capitol Hill.

His target is the Trump administration's move to reschedule cannabis.

Why the scope matters

Rescheduling one plant is hard enough. Reviewing every controlled substance at once is a different order of magnitude.

The excerpt of Marijuana Moment's report doesn't say whether Mast envisions action through Congress or the DEA, and it doesn't detail a timeline. That gap is the first thing to pin down.

The hemp problem

Federal law defines hemp as cannabis with no more than 0.3 percent delta-9 THC on a dry-weight basis. That definition ignores THCA, which converts to delta-9 THC through decarboxylation when heated, so a flower can test compliant as sold and deliver intoxicating levels once smoked.

Mast didn't say, in the quoted line, which hemp standard he'd revisit. Expect that detail to matter more than the headline.

Psilocybin and tranquilizers join the list

Psilocybin and tranquilizers sit in very different regulatory worlds. Putting them in one review suggests Mast wants the schedules judged on a common evidentiary standard.

What operators and hemp processors should watch

• Whether the scope of the administration's cannabis action changes
• Whether hemp's 0.3 percent delta-9 definition gets reopened
• Whether THCA flower and conversion-derived cannabinoids get swept in

Bigger asks usually move slower. That's an editorial read, not a forecast.

Where this stands

For full background on the federal process, see the CannIntel topic hub on DEA marijuana rescheduling.

Watch for any follow-up from Mast's office or the DEA on whether hemp and THCA fall inside the review's scope. Until then, the picture is unsettled. Expect enforcement to vary.